Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
BHP$77.60-0.98(-1.25%)Australian shares slip below 9,000 level as AI regulation fears hit miners, tech7:52:12 PM ETPH$884.17-25.32(-2.78%)Parker-Hannifin Corporation (PH) Q1 2027 Earnings Call Transcript7:34:40 PM ETAAPL$343.50-6.06(-1.73%)Can Companies Stop Their Shares From Being Tokenized? Many Big Names Say Yes7:33:37 PM ETABNB$188.69+12.32(+6.99%)Airbnb Q3 Earnings Call Highlights7:15:30 PM ETNVDA$183.76+2.16(+1.19%)Nvidia Stock Just Crashed 22%. Jim Cramer Says It's the Cheapest in a Decade7:09:51 PM ETABNB$188.69+12.32(+6.99%)Airbnb Is Growing Again—and Even It's Surprised7:09:00 PM ETBX$120.00-5.58(-4.44%)MEDIA-Blackstone doubles lock-up periods for some Asian investors - FT7:06:27 PM ETMU$680.98-114.48(-14.39%)High Bandwidth Memory Market Outlook 2032: USD 15.99 Billion Valuation Driven by Advancements in Semiconductor Packaging | Mordor Intelligence7:00:00 PM ETJNJ$271.51-4.87(-1.76%)UPDATE 2-FDA grants J&J accelerated approval for head and neck cancer treatment6:53:59 PM ETNET$281.50+36.99(+15.13%)Cloudflare's stock mounts a big comeback after fastest sales surge in nearly 4 years6:50:00 PM ETPLTR$155.25-16.49(-9.60%)Palantir Is Down 16% From Its High. History Suggests This Is What Happens Next.6:45:00 PM ETNVDA$183.76+2.16(+1.19%)House G.O.P. Leaders Ask Nvidia's Huang to Speak in Closed-Door Briefing6:39:27 PM ETSNDK$841.00-196.18(-18.91%)Sandisk: This Is A Golden Opportunity6:18:30 PM ETPNC$226.750.00(0.00%)UPDATE 1-PNC names Alexander Overstrom as CFO, succeeding Robert Reilly6:11:49 PM ETAMD$419.45-69.24(-14.17%)Cathie Wood Just Sold AMD Stock and Bought This AI Chip Stock Instead6:00:00 PM ETBN$41.50-0.26(-0.62%)Brookfield Infrastructure Announces Update on Simplification5:50:00 PM ETVOYA-PB$23.360.00(0.00%)Corporate Insight Releases Research Series on AI Leaders in Financial Services5:48:25 PM ETJNJ$271.51-4.87(-1.76%)UPDATE 1-FDA grants J&J accelerated approval for head and neck cancer treatment5:47:37 PM ETCI$301.48-3.91(-1.28%)The Cigna Group (CI) Q3 2026 Earnings Call Transcript5:44:34 PM ETJNJ$271.51-4.87(-1.76%)FDA grants J&J accelerated approval for head and neck cancer treatment5:43:49 PM ETABNB$188.69+12.32(+6.99%)Airbnb says it's launching an AI travel agent in the first half of 20275:40:55 PM ETEOG$144.890.00(0.00%)UPDATE 3-US shale producer EOG Resources beats profit estimates on higher crude prices5:40:05 PM ETAMZN$258.00-8.19(-3.08%)Stock Market Today, Nov. 5: Amazon Shares Slide as Technology Selloff Erases Early Gains5:39:37 PM ETCNQ$49.06+0.14(+0.29%)Canadian Natural: Strong Results, 10%+ Yield5:39:28 PM ET

VCYT · NASDAQ

Veracyte, Inc.

$24.16 -28.29 (-53.94%)

Company overview

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers the Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine whether patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.9B
Employees
824
Headquarters
South San Francisco, CA
Website
veracyte.com
CEO
Marc A. Stapley
Listed
October 30, 2013
P/E
21.81
Dividend yield
0.00%

Company financials

Revenue
$542M
Gross profit
$386M
Operating income
$67.5M
EBITDA
$106M
Net income
$88M
EPS
$1.11
Total assets
$1.4B
Total debt
$39.3M
Gross margin
71.31%
Net margin
16.25%
Earnings yield
4.58%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

31.0638.8146.5654.3162.06
VCYT 1D NASDAQ O52.35H52.76L49.29C52.52+2.23 (+4.43%)Vol1.91M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
VCYTVeracyte, Inc. Legal Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT) PR Newswire
VCYTVeracyte, Inc. Legal VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc. GlobeNewswire
VCYTVeracyte, Inc. Press release Global Real-World Evidence (RWE) Oncology Solutions Market Size, Share, Trends and Forecast 2026-2036 | AI, Precision Medicine, and Value-Based Care Drive 12.2% CAGR to $3.08 Billion GlobeNewswire
VCYTVeracyte, Inc. Stock news What Veracyte (VCYT) Said on Its Q3 Earnings Call MarketBeat
VCYTVeracyte, Inc. Stock news Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates Zacks Investment Research
VCYTVeracyte, Inc. Stock news Veracyte Q3 revenue beats estimates on Afirma growth; cuts testing revenue outlook Reuters
VCYTVeracyte, Inc. Press release Veracyte Announces Third Quarter 2026 Financial Results GlobeNewswire
VCYTVeracyte, Inc. Press release Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026 GlobeNewswire
VCYTVeracyte, Inc. Press release Veracyte to Participate in Upcoming Investor Conferences GlobeNewswire
VCYTVeracyte, Inc. Stock news Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks Investment Research
CLH Stock news Artisan Mid Cap Fund Q3 2026 Portfolio Update Seeking Alpha
VCYTVeracyte, Inc. Press release Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer GlobeNewswire
VCYTVeracyte, Inc. Stock news Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell? Defense World
VCYTVeracyte, Inc. Press release Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 GlobeNewswire
VCYTVeracyte, Inc. Press release Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test GlobeNewswire
VCYTVeracyte, Inc. Press release Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 GlobeNewswire
VCYTVeracyte, Inc. Press release Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation GlobeNewswire
VCYTVeracyte, Inc. Stock news Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 GlobeNewswire
VCYTVeracyte, Inc. Stock news Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Zacks Investment Research
VCYTVeracyte, Inc. Stock news Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT Defense World
See more
FAQ

Questions about Veracyte, Inc.

What does Veracyte, Inc. do?
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers the Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine whether patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc.
What is VCYT's market cap?
Veracyte, Inc. (VCYT) is a listed stock with a live quote. The latest market cap on this page is $1.9B.
Where is Veracyte, Inc. headquartered?
Veracyte, Inc. is headquartered in South San Francisco, CA.
How do I get VCYT news from the API?
Call GET /v1/news?tickers=VCYT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does VCYT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VCYT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the VCYT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs